Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours

Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce hormones which result in a variety of symptoms. However, approximately 75% of NETs are considered non-functional meaning that they do not result in hormone overproduction. The main treatment for both functional and non-functional NETs is somatostatin analogues (SSA, a type of inhibitory hormone). These drugs slow tumour growth and reduce hormone production. Over time, the majority of patients will experience tumour grow

Trial Details

NCT ID
NCT06345079
Phase
PHASE2
Sponsor
Australasian Gastro-Intestinal Trials Group
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Cessation of somatostatin analogues
  • Continuation of somatostatin analogues
Locations (sample)
  • Sydney, New South Wales, Australia|-33.86785,151.20732
  • Wollongong, New South Wales, Australia|-34.424,150.89345
  • Brisbane, Queensland, Australia|-27.46794,153.02809
  • Adelaide, South Australia, Australia|-34.92866,138.59863
  • Melbourne, Victoria, Australia|-37.814,144.96332

Key Eligibility Criteria

  • Adults over 18 years of age with well or moderately differentiated mid or hindgut neuroendocrine tumour, or pancreatic neuroendocrine tumour, metas…
  • Must have measurable disease on triphasic CT/MRI as per RECIST 1.1.
  • Ki67 ≤ 20% AND mitotic count 20 per HPF (i.e., WHO grade 1 or 2)
  • Patient has been receiving growth-controlling doses of SSA for at least 12 weeks prior to study entry. This is a minimum of 30 mg Octreotide or120m…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →